New drug aims to fight esophageal cancer when others fail

NCT ID NCT06304974

Ongoing Disease control Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jul 24, 2026 · Updated 3 times

Summary

This phase 3 trial tests a new drug called BL-B01D1 against standard chemotherapy for people with advanced esophageal cancer that has worsened after initial treatment. About 497 participants will receive either the new drug or one of several chemotherapies. The goal is to see if BL-B01D1 can slow cancer growth or improve survival.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: BL-B01D1 (also called iza-bren or izalontamab brengitecan)
What this could lead to: If it works, this could offer a new second-line treatment option for people with advanced esophageal cancer that has stopped responding to standard therapy.
What could go wrong: This is an early-stage phase 3 trial, so results are not yet known. The new drug may not work better than existing chemotherapy and could have side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ESOPHAGEAL SQUAMOUS CELL CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

esophageal squamous cell carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ESOPHAGEAL SQUAMOUS CELL CARCINOMA

Contacts and locations

Locations

Beijing Cancer Hospital

Beijing, Beijing Municipality, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.